Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | Upcoming studies investigating linvoseltamab in myeloma

Faith Davies • 9 Apr 2024
AACR 2024
Multiple Myeloma Antibodies Linvoseltamab
LINKER-MM1

Faith Davies, MD, MRCP, MRCPath, FRCPath, NYU Langone Medical Center, New York, NY, briefly outlines the upcoming studies investigating linvoseltamab in patients with multiple myeloma (MM). The LINKER-MM1 trial (NCT03761108) assessed the agent in patients with triple-class refractory disease. New trials will move it into earlier lines of therapy and the newly diagnosed setting, both alone and in combination with transplant. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Faith Davies

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
1:26
Identifying high-risk smoldering myeloma & minimizing treatment-related toxicity
Faith Davies • 26 Aug 2022
1:49
Factors to consider when sequencing therapies in myeloma
Faith Davies • 26 Aug 2022
2:48
The barriers to a cure for multiple myeloma
Faith Davies • 26 Aug 2022

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals